Gail MaderisPresident and CEO at Antiva Biosciences
Gail Maderis is President & CEO of Antiva Biosciences, a venture-backed biopharmaceutical company pioneering topical antiviral therapies against HPV. Previously, Ms. Maderis led BayBio, Northern California’s life science industry organization. From 2003-2009, she served as President and CEO of Five Prime Therapeutics, a protein discovery company focused on immuno-oncology. Ms. Maderis held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology (GZMO). She currently serves on the boards of NovaBay Pharmaceuticals (NBY), Valitor, BIO Emerging Companies, and is a Trustee of the U.C. Berkeley Foundation. In 2018, Ms. Maderis was named one of the Most Admired CEOs by the SF Business Times. She received a BS in business from UC Berkeley and an MBA from Harvard Business School.